Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialHelen M. Colhoun, John Fuller, D. J. Betteridge et al.|The Lancet|2004Cited by 3.8k
Vascular Risk Factors and Diabetic NeuropathySolomon Tesfaye, John Fuller, Nish Chaturvedi et al.|New England Journal of Medicine|2005Cited by 1.3k
Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetesNish Chaturvedi, John Fuller, Anne-Katrin Sjolie et al.|The Lancet|1998Cited by 743
Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trialsNish Chaturvedi, Anne Katrin Sjølie, Massimo Porta et al.|The Lancet|2008Cited by 450
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialAnne Katrin Sjølie, Nish Chaturvedi, Ronald Klein et al.|The Lancet|2008Cited by 432